Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. In this study, mice with streptozotocin- and high-fat diet-induced diabetes and NASH were subcutaneously treated with liraglutide or saline (control) for 14 weeks. Glycemic control, hepatocarcinogenesis, and liver histology were compared between the groups. Fasting blood glucose levels were significantly lower in the liraglutide group than in the control group (210.0 ± 17.3 mg/dL vs. 601.8 ± 123.6 mg/dL), and fasting insulin levels were significantly increased by liraglutide (0.18 ± 0.06 ng/mL vs. 0.09 ± 0.03 ng/mL). Liraglutide completely suppressed hepatocarcinogenesis, whereas HCC was observed in all control mice (average tumor count, 5.5 ± 3.87; average tumor size, 8.1 ± 5.0 mm). Liraglutide significantly ameliorated steatosis, inflammation, and hepatocyte ballooning of non-tumorous lesions in the liver compared with the control findings, and insulin-positive β-cells were observed in the pancreas in liraglutide-treated mice but not in control mice. In conclusion, liraglutide ameliorated NASH and suppressed hepatocarcinogenesis in diabetic mice. GLP-1 receptor agonists can be used to improve the hepatic outcome of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a mouse model induced with NASH-related HCC, treatment with liraglutide (a type of GLP-1RA) was shown to prevent the progression of hepatocellular carcinoma.518 This was observed through improved glycemic control, reduced occurrence of liver cancer, and better liver histology compared to the control group.518”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [518]
In the citing paper
“In mouse models, liraglutide has been shown to completely suppress hepatocarcinogenesis.”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [100]
In the citing paper
“Moreover, the long-term suppression of NASH and the favorable anti-oncogenic pathways exhibited by the GLP-1 RAs treatment could reduce the risk of de novo HCC and recurrence [100,139].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696 · cited 1×
“According to epidemiological studies, increased body weight is associated with an increased risk of liver cancer and increased death rates for liver cancer [26,27].”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602 · cited 1×
“AMP-activated protein kinase inhibits the mechanistic target of rapamycin complex-1 [41].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“Recently, studies of incretin-based therapies have focused on both their ability to improve hyperglycemia and their multiple mechanisms of action [7,8].”
BackgroundArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“In humans, previous studies including our clinical trial demonstrated that liraglutide improved the hepatic outcome of NAFLD including serological and histological assessments along with an improvement in glycemic control [13,14].”
ResultNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Nonalcoholic fatty liver disease covers a spectrum of liver diseases that range from benign simple steatosis to hepatic inflammation and fibrosis resulting from nonalcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (HCC) [2,3].”
BackgroundGlobal perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858
Bhaskaran, K., Douglas, I., Forbes, H., dos-Santos-Silva, I., Leon, D. A., & Smeeth, L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60892-8 · Cited by 1,707 · cited 1×
“According to epidemiological studies, increased body weight is associated with an increased risk of liver cancer and increased death rates for liver cancer [26,27].”
BackgroundAMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619 · cited 1×
“AMP-activated protein kinase activation causes cell cycle arrest, which is associated with the stabilization of p53 and the cyclin-dependent kinase inhibitors p21 and p27 [39,40].”
BackgroundNonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
Bugianesi, E., Leone, N., Vanni, E., Marchesini, G., Brunello, F., Carucci, P., Musso, A., De Paolis, P., Capussotti, L., Salizzoni, M., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34168 · Cited by 1,439
Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
Starley, B. Q., Calcagno, C. J., & Harrison, S. A. (2010) · Hepatology · doi:10.1002/hep.23594 · Cited by 1,336 · cited 1×
“Multiple retrospective studies have evaluated HCC in cryptogenic cirrhosis, supporting the notion that NASH accounts for a large proportion of cryptogenic cirrhosis cases and these lesions can progress to HCC [4].”
BackgroundHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 1×
“Hepatocyte apoptosis positively correlates with liver disease severity and hepatic fibrosis [49].”
BackgroundNew trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S.-U., & Wong, V. W.-S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,083 · cited 3×
“However, advanced liver fibrosis is observed at a certain prevalence in lean NAFLD [29,30], which suggests that there might be a potential mechanism that promotes liver fibrosis in lean NAFLD.”
BackgroundMolecular mechanisms of cancer development in obesity
Khandekar, M. J., Cohen, P., & Spiegelman, B. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3174 · Cited by 907 · cited 1×
“Obese people generally have insulin resistance, and this is often associated with elevated levels of circulating insulin [28].”
BackgroundLiang, J., Shao, S. H., Xu, Z.-X., Hennessy, B., Ding, Z., Larrea, M., Kondo, S., Dumont, D. J., Gutterman, J. U., Walker, C. L., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1537 · Cited by 866 · cited 1×
“AMP-activated protein kinase activation causes cell cycle arrest, which is associated with the stabilization of p53 and the cyclin-dependent kinase inhibitors p21 and p27 [39,40].”
BackgroundThe Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“Glucagon-like peptide-1 enhances glucose-stimulated insulin secretion from β-cells [19], stimulates proliferation and neogenesis, and inhibits β-cell apoptosis [20].”
BackgroundMarrero, J. A., Fontana, R. J., Su, G. L., Conjeevaram, H. S., Emick, D. M., & Lok, A. S. (2002) · Hepatology · doi:10.1002/hep.1840360609 · Cited by 660 · cited 1×
“In these studies, 6%–29% of patients with cryptogenic cirrhosis developed HCC [5,6].”
BackgroundDing, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Apoptosis: The nexus of liver injury and fibrosis
Canbay, A., Friedman, S., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20051 · Cited by 527 · cited 1×
“Hepatocyte apoptosis is mediated by lipid accumulation, cellular stress derived from oxidative metabolic disorder, cytokine alterations, and mitochondrial dysfunction [48].”
BackgroundAMPK: A Target for Drugs and Natural Products With Effects on Both Diabetes and Cancer
Hardie, D. G. (2013) · Diabetes · doi:10.2337/db13-0368 · Cited by 458 · cited 1×
“AMP-activated protein kinase is also associated with the prevention of cancer development [38].”
BackgroundNew targets of β-catenin signaling in the liver are involved in the glutamine metabolism
Cadoret, A., Ovejero, C., Terris, B., Souil, E., Lévy, L., Lamers, W. H., Kitajewski, J., Kahn, A., & Perret, C. (2002) · Oncogene · doi:10.1038/sj.onc.1206118 · Cited by 410
Svegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · cited 1×
“Furthermore, GLP-1 slows gastrointestinal motility and increases satiety with reduced food intake [9].”
BackgroundFujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355 · cited 3×
“This mouse model progresses from NAFLD to NASH at 8 weeks of age and develops to HCC at 16 weeks of age [15].”
BackgroundInfluentialGlucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Apoptosis and non-alcoholic fatty liver diseases
Kanda, T., Matsuoka, S., Yamazaki, M., Shibata, T., Nirei, K., Takahashi, H., Kaneko, T., Fujisawa, M., Higuchi, T., Nakamura, H., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i25.2661 · Cited by 270 · cited 1×
“Hepatocyte apoptosis is a key mediator of liver injury, inflammation, and fibrosis in chronic liver diseases including NAFLD [47].”
BackgroundSelf-citationHui, H., Wright, C., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 223 · cited 1×
“Trans-differentiation of α-cells and pancreatic ductal cells to β-cells in rodents treated with GLP-1 has been reported [21,22].”
BackgroundMatsumoto, K., Miyake, S., Yano, M., Ueki, Y., Yamaguchi, Y., Akazawa, S., & Tominaga, Y. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1562 · Cited by 212 · cited 1×
“Racial differences in β-cell function are well known, and β-cell function is lower in Asians [33].”
BackgroundMells, J. E., Fu, P. P., Sharma, S., Olson, D., Cheng, L., Handy, J. A., Saxena, N. K., Sorescu, D., & Anania, F. A. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00274.2011 · Cited by 202 · cited 1×
“Liraglutide ameliorates hepatic steatosis in mice with diet-induced NASH [12].”
BackgroundMusso, G., Gambino, R., Biroli, G., Carello, M., Faga, E., Pacini, G., De Michieli, F., Cassader, M., Durazzo, M., Rizzetto, M., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.00297.x · Cited by 192 · cited 1×
“demonstrated the association between the severity of hepatic fibrosis and pancreatic β-cell dysfunction in NAFLD [32].”
BackgroundHyogo, H., Yamagishi, S., Iwamoto, K., Arihiro, K., Takeuchi, M., Sato, T., Ochi, H., Nonaka, M., Nabeshima, Y., Inoue, M., et al. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2007.04943.x · Cited by 187
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · cited 1×
“In humans, previous studies including our clinical trial demonstrated that liraglutide improved the hepatic outcome of NAFLD including serological and histological assessments along with an improvement in glycemic control [13,14].”
ResultSelf-citationKoehler, J. A., Kain, T., & Drucker, D. J. (2011) · Endocrinology · doi:10.1210/en.2011-1201 · Cited by 136 · cited 1×
“Activation of cAMP and PKA by exenatide was confirmed in an in vitro study using hepatoma, colon cancer, and breast cancer cells [43,44].”
BackgroundPhillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 132 · cited 1×
“Recently, studies of incretin-based therapies have focused on both their ability to improve hyperglycemia and their multiple mechanisms of action [7,8].”
BackgroundGlucagon-Like Peptide 1 Increases β-Cell Regeneration by Promoting α- to β-Cell Transdifferentiation
Lee, Y.-S., Lee, C., Choung, J.-S., Jung, H.-S., & Jun, H.-S. (2018) · Diabetes · doi:10.2337/db18-0155 · Cited by 122 · cited 1×
“Trans-differentiation of α-cells and pancreatic ductal cells to β-cells in rodents treated with GLP-1 has been reported [21,22].”
BackgroundLigumsky, H., Wolf, I., Israeli, S., Haimsohn, M., Ferber, S., Karasik, A., Kaufman, B., & Rubinek, T. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1585-0 · Cited by 121 · cited 1×
“Activation of cAMP and PKA by exenatide was confirmed in an in vitro study using hepatoma, colon cancer, and breast cancer cells [43,44].”
BackgroundJojima, T., Wakamatsu, S., Kase, M., Iijima, T., Maejima, Y., Shimomura, K., Kogai, T., Tomaru, T., Usui, I., & Aso, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205237 · Cited by 120 · cited 1×
“Recent studies demonstrated that different hypoglycemic agents, including sodium glucose transporter inhibitor 2 inhibitors and dipeptidyl peptidase 4 inhibitors, suppressed the development of HCC following the improvement of glycemic control in a similar mouse model as that used in the present study [23,24].”
ResultAn overview of the pharmacokinetics, efficacy and safety of liraglutide
Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 91 · cited 1×
“A once-daily subcutaneous formulation was recently licensed in the United States, Europe, and Japan for the treatment of type 2 diabetes [10,11].”
Backgroundde Mesquita, F. C., Guixé‐Muntet, S., Fernández‐Iglesias, A., Maeso‐Díaz, R., Vila, S., Hide, D., Ortega‐Ribera, M., Rosa, J. L., García‐Pagán, J. C., Bosch, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02866-y · Cited by 84
Bello, B. D., de la Rosa, L. E. S., Campanini, N., Tinelli, C., Viera, F. T., D’Ambrosio, G., Rossi, S. M., & Silini, E. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1978 · Cited by 82 · cited 1×
“For immunohistochemistry, the cryosections were stained overnight at 4 ◦C with optimal dilutions of anti-glutamine synthetase (Cat# MAB302, Chemicon International, Temecula, CA, USA) to confirm the tumor lesion as HCC [55,56] and anti-insulin antibodies (Cat# MAB1417, R&D Systems, Minneapolis, MN, USA) to identify pan…”
MethodTobari, M., Hashimoto, E., Taniai, M., 五十嵐悠一, Kodama, K., Kogiso, T., Tokushige, K., Nishino, T., & Hashimoto, N. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14585 · Cited by 69 · cited 2×
“However, advanced liver fibrosis is observed at a certain prevalence in lean NAFLD [29,30], which suggests that there might be a potential mechanism that promotes liver fibrosis in lean NAFLD.”
BackgroundLi, Z., Feng, P.-P., Zhao, Z.-B., Zhu, W., Gong, J.-P., & Du, H.-M. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.12.149 · Cited by 65 · cited 1×
“reported that liraglutide increased the ratio of M2/M1 Kupffer cells in the liver of high fat diet-fed mice [45].”
BackgroundZhou, M., Mok, M. T. S., Sun, H., Chan, A. W. H., Huang, Y., Cheng, A. S. L., & Xu, G. (2017) · Oncogene · doi:10.1038/onc.2017.38 · Cited by 63 · cited 1×
“reported that injection of exenatide, a GLP-1 agonist, significantly reduced diethylnitrosamine-induced hepatocellular carcinoma in both low-fat low-carbohydrate- and high-fat high-carbohydrate-fed mice, which suggests that exenatide prevented hepatocarcinogenesis independent of obesity and NASH [42].”
BackgroundGreene, M. W., Burrington, C. M., Ruhoff, M. S., Johnson, A. K., Chongkrairatanakul, T., & Kangwanpornsiri, A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.168575 · Cited by 57
Liraglutide in clinical practice: dosing, safety and efficacy: Liraglutide in practice
Peterson, G. E., & Pollom, R. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02498.x · Cited by 55 · cited 1×
“A once-daily subcutaneous formulation was recently licensed in the United States, Europe, and Japan for the treatment of type 2 diabetes [10,11].”
BackgroundWan, S., & Sun, H. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7347 · Cited by 55 · cited 1×
“7, elucidated that GLP-1 agonists increase M2 macrophage-related markers and the secretion of the anti-inflammatory cytokine Interleukin-10 and revealed that GLP-1 agonist induces macrophages to develop the M2 phenotype [46].”
BackgroundGLP-1 contributes to increases in PGC-1α expression by downregulating miR-23a to reduce apoptosis
Wang, C., Li, Q., Wang, W., Guo, L., Guo, C. Y., Sun, Y., & Zhang, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.08.092 · Cited by 50 · cited 1×
“Recently, it was reported that GLP-1 decreased miR-23a expression and Bcl-2-associated X protein pathway, and attenuated hepatic apoptosis in HepG2 cells cultured in high glucose conditions [50].”
BackgroundJiang, J. X., Chen, X., Fukada, H., Serizawa, N., Devaraj, S., & Török, N. J. (2013) · Hepatology · doi:10.1002/hep.26491 · Cited by 49
Kawaguchi, T., Nakano, D., Koga, H., & Torimura, T. (2018) · Liver Cancer · doi:10.1159/000491763 · Cited by 49 · cited 1×
“Recent studies demonstrated that different hypoglycemic agents, including sodium glucose transporter inhibitor 2 inhibitors and dipeptidyl peptidase 4 inhibitors, suppressed the development of HCC following the improvement of glycemic control in a similar mouse model as that used in the present study [23,24].”
ResultKwon, D. Y., Kim, Y. S., Ahn, I. S., Kim, D. S., Kang, S., Hong, S. M., & Park, S. (2009) · Journal of Pharmacological Sciences · doi:10.1254/jphs.09178fp · Cited by 44 · cited 1×
“Glucagon-like peptide-1 enhances glucose-stimulated insulin secretion from β-cells [19], stimulates proliferation and neogenesis, and inhibits β-cell apoptosis [20].”
BackgroundSiddiqui, M. S., Cheang, K. L., Luketic, V. A., Boyett, S. L., Idowu, M. O., Patidar, K. R., Puri, P., Matherly, S. C., Stravitz, R. T., Sterling, R. K., et al. (2015) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-3627-7 · Cited by 35 · cited 1×
“It is reported that pancreatic β-cell function is impaired in NASH [31].”
BackgroundSoftic, S., Kirby, M., Berger, N. G., Shroyer, N. F., Woods, S. C., & Kohli, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038952 · Cited by 33 · cited 1×
“Interestingly, hypoinsulinemia, similar to hyperinsulinemia, independently aggravates fatty liver through fatty acid transport protein 2 (FATP2) or FATP5 expression [25].”
BackgroundYao, Y., Li, Q., Wang, W., Zhang, J., Gao, P., & Xu, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494235 · Cited by 32 · cited 1×
“Another study elucidated that GLP-1 enhances ATP binding cassette subfamily a member 1-dependent cholesterol efflux and reduces hepatocyte apoptosis [51].”
BackgroundWu, L., Liu, Y. C., Shi, L., & Lu, K. (2015) · Genetics and Molecular Research · doi:10.4238/2015.december.29.17 · Cited by 16 · cited 1×
“Liraglutide inhibits the activation of HSCs and α-smooth muscle actin expression by blocking the p38 mitogen-activated protein kinase signaling pathway in vitro [52].”
Background
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“This pathway could represent one of the protective mechanisms against HCC development exerted by GLP-1 RAs.”
BackgroundInfluentialTong, G., Peng, T., Chen, Y., Sha, L., Dai, H., Xiang, Y., Zou, Z., He, H., & Wang, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901559 · Cited by 218
“Previous studies have shown that GLP1 receptor agonists play an important role in the occurrence and development of a variety of tumor cells (Liu et al., 2019; Kojima et al., 2020; Mao et al., 2021).”
BackgroundCurrent and emerging strategies for the prevention of hepatocellular carcinoma
Yeo, Y. H., Abdelmalek, M. F., Khan, S. A., Moylan, C. A., Rodriquez, L. M., Villanueva, A., & Yang, J. D. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01021-z · Cited by 111
“Investigations showed that GLP1 treatment was associated with a diminished risk of HCC in MASH-driven HCC mouse models 70,71 .”
Pοlyzos, S. A., Chrysavgis, L., Vachliotis, I. D., Chartampilas, E., & Cholongitas, Ε. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.04.010 · Cited by 97
Metadata
- Authors
- Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., & Anzai, K.
- Affiliations
- Saga University (JP)
- Kyushu University (JP)
- Kurume University (JP)
- Corresponding author
- Anzai, Keizo
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-08-10
- Volume
- 21
- Issue
- 16
- Pages
- 5722
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7460814
- OpenAlex
- W3047956076
- Cited by
- 69
- References
- 58
- Citations by year
- 2026: 13 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 3
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, liraglutide, nonalcoholic steatohepatitis, hepatocellular carcinoma, hepatocarcinogenesis, diabetes mellitus, streptozotocin-induced diabetes, high-fat diet, hepatic steatosis, liver inflammation, hepatocyte ballooning, insulin, pancreatic beta cells, glycemic control
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Disease Models, Animal, Carcinoma, Hepatocellular, Hypoglycemic Agents, Insulin, Liver Neoplasms, Male, Mice, Inbred C57BL, Streptozocin, Treatment Outcome, Mice, Diet, High-Fat, Carcinogenesis, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.